Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony R Mato

Showing results (1-10 of 97) with videos related to

Pageof 10
Sort By:
PET Clinics|May 10, 2016
Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with LymphomaAnthony R Mato, Andre Goy
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2017
Emerging Strategies in Treating Double Hit LymphomasChadi Nabhan, Anthony R Mato
Clinical Advances in Hematology & Oncology : H&O|April 12, 2017
BCL-2 as a therapeutic target in chronic lymphocytic leukemiaCatherine Daniel, Anthony R Mato
Cancer Journal (Sudbury, Mass.)|November 26, 2019
Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted TherapiesPrioty Islam, Anthony R Mato
Current Hematologic Malignancy Reports|May 9, 2020
Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and OpportunitiesPrioty Islam, Anthony R Mato
Cancer Management and Research|April 8, 2020
Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging DataKrista Isaac, Anthony R Mato
Blood Advances|February 11, 2021
Overcoming resistance to targeted therapies in chronic lymphocytic leukemiaSigrid S Skånland, Anthony R Mato
Drug Design, Development and Therapy|March 10, 2021
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic LeukemiaJoanna M Rhodes, Anthony R Mato
Clinical Lymphoma, Myeloma & Leukemia|October 7, 2016
Richter's Transformation in the Era of Kinase Inhibitor Therapy: A ReviewEmily C Ayers, Anthony R Mato
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemiaBruce D Cheson, Anthony R Mato
Pageof 10

Showing results (1-10 of 97) with videos related to

Sort By:
Pageof 10
PET Clinics|May 10, 2016
Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with LymphomaAnthony R Mato, Andre Goy
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2017
Emerging Strategies in Treating Double Hit LymphomasChadi Nabhan, Anthony R Mato
Clinical Advances in Hematology & Oncology : H&O|April 12, 2017
BCL-2 as a therapeutic target in chronic lymphocytic leukemiaCatherine Daniel, Anthony R Mato
Cancer Journal (Sudbury, Mass.)|November 26, 2019
Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted TherapiesPrioty Islam, Anthony R Mato
Current Hematologic Malignancy Reports|May 9, 2020
Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and OpportunitiesPrioty Islam, Anthony R Mato
Cancer Management and Research|April 8, 2020
Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging DataKrista Isaac, Anthony R Mato
Blood Advances|February 11, 2021
Overcoming resistance to targeted therapies in chronic lymphocytic leukemiaSigrid S Skånland, Anthony R Mato
Drug Design, Development and Therapy|March 10, 2021
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic LeukemiaJoanna M Rhodes, Anthony R Mato
Clinical Lymphoma, Myeloma & Leukemia|October 7, 2016
Richter's Transformation in the Era of Kinase Inhibitor Therapy: A ReviewEmily C Ayers, Anthony R Mato
Clinical Advances in Hematology & Oncology : H&O|April 12, 2021
The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemiaBruce D Cheson, Anthony R Mato
Pageof 10